Cargando…

Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study

OBJECTIVES: Patients with hip fracture are typically characterised by extensive comorbidities and excess mortality. Methods that account for a wide range of comorbidities are needed when attempting to identify causal associations in registry-based studies. We aimed to study the association between t...

Descripción completa

Detalles Bibliográficos
Autores principales: Holvik, Kristin, Hjellvik, Vidar, Karlstad, Øystein, Gunnes, Nina, Hoff, Mari, Tell, Grethe S, Meyer, Haakon E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062812/
https://www.ncbi.nlm.nih.gov/pubmed/35501100
http://dx.doi.org/10.1136/bmjopen-2021-057823
_version_ 1784699030392012800
author Holvik, Kristin
Hjellvik, Vidar
Karlstad, Øystein
Gunnes, Nina
Hoff, Mari
Tell, Grethe S
Meyer, Haakon E
author_facet Holvik, Kristin
Hjellvik, Vidar
Karlstad, Øystein
Gunnes, Nina
Hoff, Mari
Tell, Grethe S
Meyer, Haakon E
author_sort Holvik, Kristin
collection PubMed
description OBJECTIVES: Patients with hip fracture are typically characterised by extensive comorbidities and excess mortality. Methods that account for a wide range of comorbidities are needed when attempting to identify causal associations in registry-based studies. We aimed to study the association between the prescription-based Rx-Risk Comorbidity Index (abbreviated Rx-Risk) and mortality by history of hip fracture, and to quantify the contribution of Rx-Risk in explaining the excess mortality after hip fracture. SETTING: In this prospective study, we used nationwide registry data from outpatient care. Rx-Risk was based on filled prescriptions recorded in the Norwegian Prescription Database. Medications were mapped to 46 comorbidity categories by Anatomical Therapeutic Chemical code. Information on hip fractures during 1994–2013 was available from the Norwegian Epidemiologic Osteoporosis Studies hip fracture database, and year of death was obtained from Statistics Norway. We estimated 1-year mortality risk (January through December 2014) according to Rx-Risk score based on dispensed prescriptions in 2013, history of hip fracture, age and sex using Poisson regression. PARTICIPANTS: All individuals aged 65 years and older who were alive by the end of 2013 and had filled at least one prescription in an outpatient pharmacy in Norway in 2013 (n=735 968). RESULTS: Mortality increased exponentially with increasing Rx-Risk scores, and it was highest in persons with a history of hip fracture across the major range of Rx-Risk scores. Age- and sex-adjusted mortality risk difference according to history of hip fracture (yes vs no) was 4.4 percentage points (7.8% vs 3.4%). Adjustment for Rx-Risk score further attenuated this risk difference to 3.3 percentage points. CONCLUSIONS: History of hip fracture and comorbidity assessed by Rx-Risk are independent risk factors for mortality in the community-dwelling older population in Norway. Comorbidity explained a quarter of the excess mortality in persons with a history of hip fracture.
format Online
Article
Text
id pubmed-9062812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90628122022-05-12 Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study Holvik, Kristin Hjellvik, Vidar Karlstad, Øystein Gunnes, Nina Hoff, Mari Tell, Grethe S Meyer, Haakon E BMJ Open Epidemiology OBJECTIVES: Patients with hip fracture are typically characterised by extensive comorbidities and excess mortality. Methods that account for a wide range of comorbidities are needed when attempting to identify causal associations in registry-based studies. We aimed to study the association between the prescription-based Rx-Risk Comorbidity Index (abbreviated Rx-Risk) and mortality by history of hip fracture, and to quantify the contribution of Rx-Risk in explaining the excess mortality after hip fracture. SETTING: In this prospective study, we used nationwide registry data from outpatient care. Rx-Risk was based on filled prescriptions recorded in the Norwegian Prescription Database. Medications were mapped to 46 comorbidity categories by Anatomical Therapeutic Chemical code. Information on hip fractures during 1994–2013 was available from the Norwegian Epidemiologic Osteoporosis Studies hip fracture database, and year of death was obtained from Statistics Norway. We estimated 1-year mortality risk (January through December 2014) according to Rx-Risk score based on dispensed prescriptions in 2013, history of hip fracture, age and sex using Poisson regression. PARTICIPANTS: All individuals aged 65 years and older who were alive by the end of 2013 and had filled at least one prescription in an outpatient pharmacy in Norway in 2013 (n=735 968). RESULTS: Mortality increased exponentially with increasing Rx-Risk scores, and it was highest in persons with a history of hip fracture across the major range of Rx-Risk scores. Age- and sex-adjusted mortality risk difference according to history of hip fracture (yes vs no) was 4.4 percentage points (7.8% vs 3.4%). Adjustment for Rx-Risk score further attenuated this risk difference to 3.3 percentage points. CONCLUSIONS: History of hip fracture and comorbidity assessed by Rx-Risk are independent risk factors for mortality in the community-dwelling older population in Norway. Comorbidity explained a quarter of the excess mortality in persons with a history of hip fracture. BMJ Publishing Group 2022-05-02 /pmc/articles/PMC9062812/ /pubmed/35501100 http://dx.doi.org/10.1136/bmjopen-2021-057823 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Holvik, Kristin
Hjellvik, Vidar
Karlstad, Øystein
Gunnes, Nina
Hoff, Mari
Tell, Grethe S
Meyer, Haakon E
Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study
title Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study
title_full Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study
title_fullStr Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study
title_full_unstemmed Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study
title_short Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study
title_sort contribution of an extensive medication-based comorbidity index (rx-risk) in explaining the excess mortality after hip fracture in older norwegians: a norepos cohort study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062812/
https://www.ncbi.nlm.nih.gov/pubmed/35501100
http://dx.doi.org/10.1136/bmjopen-2021-057823
work_keys_str_mv AT holvikkristin contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy
AT hjellvikvidar contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy
AT karlstadøystein contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy
AT gunnesnina contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy
AT hoffmari contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy
AT tellgrethes contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy
AT meyerhaakone contributionofanextensivemedicationbasedcomorbidityindexrxriskinexplainingtheexcessmortalityafterhipfractureinoldernorwegiansanoreposcohortstudy